List of Excipients in Branded Drug ROBINUL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
West-Ward Pharmaceuticals Corp	ROBINUL	robinul	0641-6104	BENZYL ALCOHOL
West-Ward Pharmaceuticals Corp	ROBINUL	robinul	0641-6104	HYDROCHLORIC ACID
West-Ward Pharmaceuticals Corp	ROBINUL	robinul	0641-6104	SODIUM HYDROXIDE
West-Ward Pharmaceuticals Corp	ROBINUL	robinul	0641-6104	WATER

ROBINUL Excipient Strategy and Commercial Opportunities for Glycopyrrolate

Last updated: September 6, 2026

ROBINUL is a glycopyrrolate product family used primarily in perioperative care to reduce secretions and block vagal effects. Its commercial opportunity is not based on new-molecule exclusivity. It lies in dosage-form redesign, preservative-free delivery, pediatric and long-term-care formulations, medication-error reduction, and differentiated excipient systems that improve tolerability, stability, and administration.

What is ROBINUL and which glycopyrrolate products are commercially relevant?

ROBINUL contains glycopyrrolate, a quaternary ammonium anticholinergic that does not readily cross the blood-brain barrier. U.S. products have included injectable glycopyrrolate and oral tablets. Generic glycopyrrolate products compete with the brand in several markets. The injectable product is used mainly in anesthesia and perioperative settings, while oral glycopyrrolate is used for gastrointestinal indications and secretion control under applicable labeling. [1][2]

Product category	Active ingredient	Typical strength	Primary setting	Excipient opportunity
Injectable ROBINUL	Glycopyrrolate	0.2 mg/mL	Operating room, anesthesia, emergency care	Ready-to-use syringes, premixed bags, low-sorption containers
Oral tablets	Glycopyrrolate	1 mg, 2 mg	Chronic oral treatment	Pediatric liquids, smaller tablets, taste masking, modified release
Oral liquid	Glycopyrrolate	Variable	Pediatric, geriatric, dysphagia, palliative care	Preservative-free multidose systems, alcohol-free vehicles
Orally disintegrating products	Glycopyrrolate	Potentially 0.5-2 mg	Dysphagia and rapid administration	Taste masking, moisture protection, rapid disintegration
Long-acting formulations	Glycopyrrolate	Development-stage	Chronic secretion management	Controlled-release matrices, depot systems, reduced dosing frequency

The key formulation constraint is dose size. Glycopyrrolate is pharmacologically potent, so the active pharmaceutical ingredient represents a small fraction of the final dosage unit. Excipients control manufacturability, dose uniformity, dissolution, taste, stability, and patient acceptance.

What excipients are used in ROBINUL formulations?

Injectable formulation

The injectable product is an aqueous solution of glycopyrrolate. Sodium chloride is used for isotonicity, with pH adjustment generally performed using hydrochloric acid or sodium hydroxide. The product is supplied as a sterile parenteral preparation and is intended for injection by qualified healthcare personnel. [1]

The commercial priorities for injectable glycopyrrolate are different from those for tablets:

• Chemical stability in a low-dose aqueous solution
• Accurate delivery at a 0.2 mg/mL concentration
• Compatibility with syringes, bags, tubing, and connectors
• Protection from particulate contamination
• Sterility assurance
• Low extractables and leachables
• Reliable visual inspection
• Rapid availability in the operating room

A preservative-free presentation is commercially attractive because glycopyrrolate is commonly administered intravenously or intramuscularly in controlled clinical environments. Single-dose vials and prefilled syringes can reduce preparation steps and contamination risk.

The main excipient strategy is therefore minimalist. Each additional excipient increases the regulatory and compatibility burden without necessarily improving clinical performance.

Oral tablet formulation

Oral glycopyrrolate tablets commonly use standard direct-compression or wet-granulation excipient systems. Publicly available product information identifies conventional tablet excipients such as lactose, microcrystalline cellulose, povidone, sodium starch glycolate, colloidal silicon dioxide, and stearic acid, although composition varies by manufacturer and strength. [2][3]

Each excipient has a defined manufacturing role:

Excipient class	Typical function	Commercial relevance
Lactose or other filler	Adds bulk and improves compression	Creates lactose-intolerance and excipient-labeling considerations
Microcrystalline cellulose	Diluent and compression aid	Supports low-dose content uniformity
Povidone	Binder	Improves granule strength and tablet integrity
Sodium starch glycolate	Superdisintegrant	Promotes rapid tablet breakup
Colloidal silicon dioxide	Glidant	Improves powder flow and dose uniformity
Stearic acid or related lubricant	Reduces tooling friction	Excess levels can slow dissolution

For glycopyrrolate, content uniformity is more important than high drug loading. Poor powder segregation can produce clinically meaningful dose variation because tablets contain a low quantity of active ingredient. Excipient particle size, density, and mixing behavior are central process controls.

What formulation patents could protect glycopyrrolate products?

Legacy immediate-release glycopyrrolate tablets and injections have limited room for broad composition-of-matter protection because glycopyrrolate has been used clinically for decades. Commercially meaningful intellectual property would more likely cover a specific formulation, delivery device, manufacturing method, or clinical use.

Potential patent categories include:

1. Taste-masked oral liquids. Polymer-coated particles, ion-exchange resins, complexing agents, or multiparticulate systems could protect a formulation intended for pediatric or dysphagia populations.

2. Controlled-release tablets. Hydrophilic matrices, coated pellets, osmotic systems, or gastroretentive dosage forms could reduce dosing frequency.

3. Orally disintegrating tablets. Protection could cover a glycopyrrolate-specific combination of porous excipients, taste-masking agents, and disintegration performance.

4. Ready-to-administer injections. A patent could claim a stable glycopyrrolate solution in a particular container, concentration, pH range, or prefilled syringe configuration.

5. Combination products. A formulation combining glycopyrrolate with another perioperative or respiratory agent could create device, formulation, or method-of-use rights.

6. Manufacturing processes. Low-shear blending, granulation controls, particle engineering, and packaging methods could support process patents or trade secrets.

Patent value would depend on whether the claims cover an unavoidable commercial feature. A narrow pH or excipient claim may be designed around by a generic manufacturer. A claim covering a validated ready-to-use presentation, a specific controlled-release profile, or a clinically relevant pediatric formulation would have greater commercial value.

When does ROBINUL lose exclusivity?

ROBINUL is an old active ingredient and does not depend on current new chemical entity exclusivity. The principal competitive barriers are manufacturing approval, formulation quality, supply reliability, and any product-specific patents listed for a particular dosage form.

Exclusivity category	ROBINUL assessment
New chemical entity exclusivity	Expired for the legacy active ingredient
Orphan-drug exclusivity	Not the basis of the traditional ROBINUL franchise
Pediatric exclusivity	No broad product-level protection should be assumed
Regulatory exclusivity for a new formulation	Available only if a new product satisfies applicable FDA requirements
Orange Book patent protection	Must be assessed by product and sponsor; legacy immediate-release products generally have limited remaining protection
Generic competition	Established or commercially feasible for conventional tablets and injections

The relevant regulatory question is not when glycopyrrolate itself loses exclusivity. It is whether a new glycopyrrolate formulation receives a separate period of regulatory protection or patent protection.

A 505(b)(2) product could be commercially useful where the sponsor changes the dosage form, route, formulation, concentration, or delivery system while relying partly on existing glycopyrrolate findings. FDA treatment would depend on the extent of the change and the evidence required. [4]

What is the Orange Book status of ROBINUL?

The FDA Orange Book lists approved drug products and, where applicable, patents and exclusivity information. Orange Book analysis must be performed at the application and dosage-form level rather than by searching the ROBINUL brand alone. [5]

For conventional glycopyrrolate tablets and injections, the principal commercial risk is generic substitution rather than a pending loss of a major unexpired brand patent. A sponsor developing a new product should evaluate:

• The exact reference-listed drug
• Approved route and dosage form
• Whether the reference product is currently marketed
• Listed patents and certification requirements
• Whether the proposed product is an ANDA or 505(b)(2) candidate
• Whether the product changes the labeling, dosing frequency, or delivery system

What Paragraph IV risks affect glycopyrrolate?

Paragraph IV risk is most relevant where an innovator lists a patent against a specific formulation or delivery product. A conventional generic glycopyrrolate tablet or injection may face fewer patent barriers if no enforceable product-specific patents remain.

A differentiated product could generate a new Paragraph IV exposure if its sponsor lists formulation or method-of-use patents. The risk would increase where:

• The product has a commercially important controlled-release profile
• The formulation depends on a narrowly claimed excipient system
• The sponsor lists a patent covering a ready-to-use container or device
• The product has a high-value indication with limited substitutes

Publicly available information does not establish a major current patent litigation campaign centered on legacy ROBINUL tablets or injections. The greater risk for a new entrant is competitive substitution by established generic glycopyrrolate products.

What formulation opportunities exist for glycopyrrolate?

Pediatric oral liquid

A pediatric oral liquid is one of the clearest opportunities. Tablets create barriers for children, patients with dysphagia, and patients receiving medication through enteral tubes.

A commercially viable liquid would need:

• Accurate low-dose measurement
• Acceptable taste
• Physical and chemical stability
• Low viscosity for oral syringes and feeding tubes
• Compatibility with common enteral materials
• Preservative control
• Low sugar or sugar-free options
• Clear concentration labeling to reduce dosing errors

Glycopyrrolate has an anticholinergic taste profile that can impair adherence. Taste masking is therefore a stronger differentiator than adding conventional flavor alone. Ion-exchange resin complexes, coated microparticles, or polymeric taste barriers could support patentable differentiation.

Orally disintegrating tablet

An orally disintegrating tablet could target patients who cannot swallow conventional tablets. The main technical challenges are:

• Taste masking
• Moisture sensitivity
• Low-dose content uniformity
• Mechanical strength
• Rapid disintegration
• Packaging protection

A blister-pack presentation could improve dose portability and support adherence. The product would compete with conventional tablets on convenience rather than pharmacologic superiority.

Ready-to-administer injection

A prefilled syringe or small-volume ready-to-administer container could reduce medication preparation time in anesthesia departments. Commercial value would come from workflow efficiency and lower preparation risk.

The formulation should avoid unnecessary excipients. Key development work would involve:

• Syringe-material compatibility
• Silicone-oil interaction
• Container closure integrity
• Adsorption to surfaces
• Light exposure
• In-use stability
• Labeling and barcode integration

A ready-to-administer injectable product could be positioned for hospitals that use centralized pharmacy preparation or standardized anesthesia carts.

Low-volume concentrated injection

A concentrated presentation could reduce storage volume, but it would introduce dosing and dilution risks. Its value would be greatest in high-throughput institutional settings where pharmacy operations can control preparation. A concentration change would require careful evaluation of dosing errors and compatibility with existing administration protocols.

Modified-release oral product

A controlled-release glycopyrrolate product could reduce dosing frequency for chronic secretion management. The opportunity is technically more difficult because anticholinergic exposure must remain within a tolerable range.

A successful product would need to demonstrate:

• Reduced peak-related adverse effects
• Sustained control of secretions
• Predictable absorption
• Adequate performance in patients with variable gastrointestinal transit
• Safe use in older adults and patients with comorbidities

The formulation could support a 505(b)(2) strategy, but clinical bridging requirements may be substantial if exposure differs materially from immediate-release tablets.

How does ROBINUL compare with competing anticholinergic products?

Product	Active ingredient	Route	Main differentiation	Excipient opportunity
ROBINUL/glycopyrrolate	Glycopyrrolate	Injection, oral	Peripheral anticholinergic activity and established use	Pediatric liquids, prefilled injections, modified release
Atropine	Atropine	Injection, ophthalmic, oral in selected uses	Broader anticholinergic profile and central effects	Route-specific delivery and lower systemic exposure
Scopolamine	Scopolamine	Transdermal, injectable, oral in selected markets	Transdermal delivery	Patch adhesion, controlled release
Hyoscyamine	Hyoscyamine	Oral, sublingual	Oral antispasmodic use	Sublingual and orally disintegrating systems
Benztropine	Benztropine	Oral, injection	Central anticholinergic activity	Oral dosage-form convenience

Glycopyrrolate’s most defensible differentiation is peripheral activity and established perioperative use. A new formulation should avoid competing only on tablet price. It should target administration problems that generic tablets and vials do not solve.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can participate through platform technologies rather than through glycopyrrolate-specific raw-material sales alone.

High-value supplier opportunities

• Taste-masking polymers for pediatric liquids and orally disintegrating tablets
• Low-peroxide excipients for oxidation-sensitive aqueous products
• Direct-compression excipients optimized for low-dose uniformity
• Ready-to-use suspending systems
• Preservative alternatives for multidose oral liquids
• Low-extractables packaging components
• Prefilled syringe systems
• Moisture-barrier blister materials
• Enteral-tube-compatible vehicles
• Continuous manufacturing and low-segregation powder systems

The strongest commercial position would combine excipient supply with formulation know-how, analytical methods, and regulatory documentation. A supplier that can provide a complete drug-product platform has more negotiating leverage than one selling a commodity filler or lubricant.

What regulatory and manufacturing barriers apply?

FDA approval would require product-specific chemistry, manufacturing, and controls data. The sponsor would need to establish identity, strength, quality, purity, stability, dissolution or release performance, and container compatibility. Injectable products carry higher sterility and particulate-control requirements than oral products. [4]

Manufacturing barriers include:

• Low-dose blend uniformity
• Glycopyrrolate assay sensitivity
• Moisture control
• Tablet friability and disintegration balance
• Suspension homogeneity for liquids
• Microbial control
• Extractables and leachables
• Compatibility with administration devices
• Scale-up from laboratory to commercial batches

Geographic opportunity is strongest in the United States, Europe, Japan, and other markets with established perioperative and chronic-care demand. Emerging markets may favor low-cost tablets and injections, while high-income markets offer greater willingness to pay for prefilled injections, pediatric liquids, and adherence-oriented products.

What is the likely revenue exposure and generic launch risk?

Legacy ROBINUL products face high generic substitution risk because the active ingredient is old, the dosage forms are conventional, and multiple manufacturers can develop comparable products. Revenue exposure is greatest where sales depend on standard tablets or vials without differentiated packaging or workflow value.

A new formulation can reduce price exposure if it achieves one of four outcomes:

1. It addresses a population unable to use the incumbent dosage form.
2. It reduces hospital preparation time.
3. It improves dosing accuracy.
4. It provides clinically useful dosing-frequency reduction.

The most defensible launch sequence would typically prioritize a ready-to-administer injection or pediatric oral liquid, followed by an orally disintegrating or modified-release product. Each step raises development complexity, but each also creates greater separation from commodity generic competition.

Key Takeaways

• ROBINUL is a legacy glycopyrrolate brand with limited value from active-ingredient exclusivity.
• Excipients matter most for dose uniformity, taste masking, liquid stability, sterility, and administration convenience.
• A minimalist preservative-free injectable strategy is appropriate for perioperative use.
• Pediatric oral liquids and dysphagia-oriented products offer the clearest formulation opportunities.
• Prefilled syringes can create hospital workflow value without changing the active ingredient.
• Modified-release products may support stronger differentiation but carry greater clinical and regulatory costs.
• Generic competition is a major risk for conventional tablets and injections.
• New patent value would likely come from formulation, device, manufacturing, or method-of-use claims.
• Excipient suppliers should pursue integrated formulation platforms rather than commodity supply alone.

FAQs

Is glycopyrrolate the same drug as ROBINUL?

Yes. ROBINUL is a brand associated with glycopyrrolate products. The active ingredient is glycopyrrolate, including glycopyrrolate injection and oral tablet presentations.

Which ROBINUL dosage form has the strongest commercial opportunity?

A pediatric or dysphagia-compatible oral liquid has the strongest unmet formulation opportunity. A ready-to-administer injection has the strongest institutional workflow opportunity.

Can excipients receive patents in a glycopyrrolate product?

Yes. Patents may cover a specific excipient combination, taste-masking system, release profile, container, manufacturing process, or dosage form. Broad protection for the old active ingredient is unlikely.

Is a glycopyrrolate oral liquid suitable for a 505(b)(2) application?

Potentially. A new liquid formulation may rely partly on existing glycopyrrolate safety and efficacy findings, but the required bridging, stability, bioavailability, and clinical data depend on the formulation and labeling differences.

What is the main generic threat to ROBINUL?

The main threat is substitution by conventional generic glycopyrrolate tablets and injections. A differentiated product is less exposed when it solves a dosing, administration, pediatric, or hospital workflow problem that standard generics do not address.

References

1. U.S. Food and Drug Administration. (n.d.). Robinul injection, glycopyrrolate injection prescribing information. FDA.

2. National Library of Medicine. (n.d.). DailyMed: Glycopyrrolate tablet product labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.

4. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA.

5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.